Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Farmaceutica Remedia's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Farmaceutica Remedia's 5-Year Yield-on-Cost % or its related term are showing as below:
During the past 13 years, Farmaceutica Remedia's highest Yield on Cost was 25.63. The lowest was 1.47. And the median was 6.15.
LTS:0M8I's 5-Year Yield-on-Cost % is not ranked *
in the Medical Distribution industry.
Industry Median: 3.14 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Farmaceutica Remedia 5-Year Yield-on-Cost % Related Terms
LTS:0M8I vs MCK, COR, CAH: 5-Year Yield-on-Cost % Comparison
For the Medical Distribution subindustry, Farmaceutica Remedia's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Farmaceutica Remedia 5-Year Yield-on-Cost % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Farmaceutica Remedia's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Farmaceutica Remedia's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Farmaceutica Remedia (LTS:0M8I) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 15, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Farmaceutica Remedia and its competitors. Over the past decade, Farmaceutica Remedia's 5-Year Yield-on-Cost % has ranged from 1.47 to 25.63. According to the industry distribution chart, Farmaceutica Remedia ranks #24 out of 69 companies in the Medical Distribution industry, placing it in the top 34.8%.
Is Farmaceutica Remedia's 5-Year Yield-on-Cost % too high?
Farmaceutica Remedia's current 5-Year Yield-on-Cost % is 0.00. Over the past 10 years, this metric has ranged from a low of 1.47 to a high of 25.63. Based on the distribution chart, Farmaceutica Remedia ranks #24 out of 69 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Farmaceutica Remedia has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Farmaceutica Remedia's 5-Year Yield-on-Cost % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Farmaceutica Remedia ranks #24 out of 69 companies for 5-Year Yield-on-Cost %. This puts Farmaceutica Remedia in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 3.14. Historically, Farmaceutica Remedia's own 5-Year Yield-on-Cost % has ranged from 1.47 to 25.63 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Distribution company?
The median 5-Year Yield-on-Cost % among Medical Distribution companies is 3.14, based on 69 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Farmaceutica Remedia and its competitors. For the Medical Distribution industry, the median 5-Year Yield-on-Cost % is 3.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Farmaceutica Remedia's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farmaceutica Remedia stock overvalued right now?
Farmaceutica Remedia (LTS:0M8I) has a current 5-Year Yield-on-Cost % of 0.00. The stock's GF Value™ is lei0.23, compared to a current price of lei0.25 — trading 8.7% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Farmaceutica Remedia's overall GF Score™ is 59/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Farmaceutica Remedia (LTS:0M8I), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Farmaceutica Remedia (LTS:0M8I) Overvalued in 2026?
Based on GuruFocus' analysis, Farmaceutica Remedia stock appears to be overvalued.
The current stock price of lei0.25 is trading 8.7% above its estimated GF Value™ of lei0.23.
Key valuation signals for LTS:0M8I:
5-Year Yield-on-Cost %: 0.00
GF Value™: lei0.23 vs. price of lei0.25 (8.7% above fair value)
No single metric tells the full story. See the LTS:0M8I stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Farmaceutica Remedia SA is engaged in drug sales activities, marketing, and health products. It provides marketing and promotion services for medicines. The company offers services offered, including logistics services, medical marketing, and promotion, and pharmaceutical registrations, but also professionalism and performance differentiate the company from other competitors and position it as a partner for launching, promoting, and distributing pharmaceutical products in Romania and other countries in Eastern Europe.
59GF Score
Get the complete analysis for LTS:0M8I
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0M8I has been successfully added to your 
